Skip To Main Content
Bart S. Ferket on Muck Rack

Bart S. Ferket

As seen in: heart, Annals of Internal Medicine, Diabetes Care Magazine, Journal of Clinical Oncology, Texas Medical Center, European Urology, Journal of Cardiac Failure
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bart S.

Contact Bart S., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Parent-Reported Clinical Utility of Pediatric Genomic Sequencing

|
By Hadley Smith, Bart S. Ferket, Bruce Gelb, Lucia A. Hindorff
| Texas Medical Center
BACKGROUND AND OBJECTIVES: Genomic sequencing (GS) is increasingly used for diagnostic evaluation, yet follow-up care is not well understood. We assessed clinicians' recommendations after GS, parent-reported follow-up, and actions parents initiated in response to learning their child's GS results. METHODS: We surveyed parents of children who received GS through the Clinical Sequencing Evidence Generating Research consortium ∼5 to 7 months after return of results.
Open in Who Shared Issue with article?

Cost-Effectiveness Frameworks for Comparing Genome and Exome Sequencing Versus Conventional Diagnostic Pathways: A Scoping Review and Recommended Methods

|
By Bart S. Ferket, Zach Baldwin, Priyanka Murali, Akila Pai
| Texas Medical Center
PURPOSE: Methodological challenges have limited economic evaluations of genome sequencing (GS) and exome sequencing (ES). Our objective was to develop conceptual frameworks for model-based cost-effectiveness analyses (CEAs) of diagnostic GS/ES.
Open in Who Shared Issue with article?

Aspirin Monotherapy Is More Cost Effective than Rivaroxaban + Aspirin in Peripheral Arterial Disease Patients after Revascularization

|
By Zach Feldman, Lyndon P. James, Imani McElroy, Bart S. Ferket
| jvascsurg.org
Objectives Considerable debate exists on optimal antithrombotic therapy after lower extremity revascularization in peripheral arterial disease (PAD) patients. Multiple studies have investigated the addition of additional agents to the widely accepted aspirin monotherapy, including low-dose rivaroxaban in the Vascular Outcomes Study of Aspirin Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD (VOYAGER PAD) trial.
Open in Who Shared Issue with article?
See all 13 licensed articles (14 Total)